Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 82, Issue 4, 2011, Pages 441-446

  Thon, Niklas ^a   Eigenbrod, Sabina ^a   Grasbon Frodl, Eva M ^a   Lutz, Juergen ^a   Kreth, Simone ^a   Popperl, Gabriele ^a   Belka, Claus ^a   Kretzschmar, Hans A ^a   Tonn, Joerg Christian ^a   Kreth, Friedrich W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CONFUSION; CONTROLLED STUDY; DEPRESSION; DISORIENTATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HEART ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOCORTISOLISM; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORBIDITY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN METHYLATION; PRURITUS; PSYCHOSIS; REPRODUCIBILITY; SEQUENCE ANALYSIS; STEREOTACTIC BIOPSY; THROMBOSIS; TUMOR LOCALIZATION;

EID: 79952735750     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2010.214593     Document Type: Article

References (23)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)
4. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. (Pubitemid 40349502)
5. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008;9:29-38.
6. Kreth S, Heyn J, Grau S, et al. Identification of valid endogenous control genes for determining gene expression in human glioma. Neuro-Oncology 2010;12:570-9.
7. Thon N, Eigenbrod S, Grasbon-Frodl EM, et al. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization Grade II Gliomas. J Neuropathol Exp Neurol 2009;68:1219-28.
8. Grasbon-Frodl EM, Kreth FW, Ruiter M, et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 2007;121:2458-64. (Pubitemid 350022415)
9. Karnofsky DA, Abelmann WH, Craver LF, et al. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-56.
10. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109. (Pubitemid 47103521)
11. Kreth FW, Muacevic A, Medele R, et al. The risk of haemorrhage after image guided stereotactic biopsy of intra-axial brain tumours - a prospective study. Acta Neurochir (Wien) 2001;143:539-45.
12. Mollemann M, Wolter M, Felsberg J, et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005;113:379-85. (Pubitemid 40038704)
13. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
14. Clark SJ, Statham A, Stirzaker C, et al. DNA methylation: bisulphite modification and analysis. Nat Protoc 2006;1:2353-64.
15. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992;89:1827-31.
16. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-10. (Pubitemid 23133591)
17. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80. (Pubitemid 20195640)
18. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26:2192-7.
19. Popperl G, Kreth FW, Herms J, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 2006;47:393-403.
20. Chinot OL, Barrie M, Fuentes S, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 2007;25:1470-5. (Pubitemid 46733073)
21. Kaplan E, Meier P. Non parametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-81.
22. Cox DR. Regression model and life-tables. J Roy Stat Soc Ser B 1972:187-220.
23. Everhard S, Tost J, El AH, et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 2009;11:348-56.